Staff Profile

Dr Greystoke joined Newcastle University and the Northern Centre for Cancer Care in 2014 after 8 years spent at the University of Manchester/ Christie NHS Trust.  He is one of 3 consultants that run the Sir Bobby Robson Early Clinical Trials Centre at the Freeman hospital in Newcastle, and has a special interest in the development of new anti-cancer drugs for patients with lung cancer. He is a member of Lung CSG, leads systemic therapy research for NSCLC in the North-East, with a portfolio of Phase I-IV studies, and is the sub-specialty lead for lung cancer for the North-East England and North Cumbria NIHR CRN. In addition he is the Principle Investigator of PROSPECT-NE a study assessing molecular profiles in patients referred for early clinical studies in Newcastle and he leads the Pharmacodynamic Biomarker team at the Northern Institute for Cancer Research, Newcastle University.

Areas of expertise

• Lung Cancer
• Early Drug development
• Personalised Medicine
• Circulating Biomarkers
• Treatment of cancer in the elderly

Twitter: alastair.greyst2

Google Scholar: Click here.

• Navidi M, Phillips AW, Griffin SM, Duffield KE, Greystoke A, Sumpter K, Sinclair RCF. Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer. British Journal of Surgery 2018, 105(7), 900-906.
• Cho BC, Kim D-W, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim S-W, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2017, 12(9), 1357-1367.
• Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TRJ, Anthoney A, Ranson M, Boddy AV, Plummer R. A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer 2016, 68, 1-10.
• Hall S, Lambourne B, Aynsley E, Gardiner J, Greystoke A, Hughes A, Jones C, Leaning D, Li L, Mansy T, Margetts J, Mcdonald F, Mcmenemin R, Mulvenna P, Peedell C, Shakespeare D, Simmons T, Singhal S, Turnbull H. Crizotinib in clinical practice: the North East of England's experience. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier Ireland Ltd.
• Greystoke A, Ayub M, Rothwell DG, Morris D, Burt D, Hodgkinson CL, Morrow CJ, Smith N, Aung K, Valle J, Carter L, Blackhall F, Dive C, Brady G. Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. Molecular Oncology 2016, 10(2), 282-291.
• Dean E, Steele N, Arkenau HT, Blackhall F, Haris NM, Lindsay C, Rafii S, Califano R, Plummer R, Voskoboynik M, Summers YJ, Ghiorghiu D, Dymond A, So K, Greystoke A. SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. In: 41st ESMO Congress (ESMO 2016). 2016, Copenhagen, Denmark: Oxford University Press.
• Greystoke A, Hogarth L, Patterson M, Williams I, Ness T, Georgiadis K, Bolt L, Bettison I, Turner D, Jamieson D, Simmons T, Hughes A, Jaedicke K, Gardiner J, Mulvenna P, Leaning D, Bradshaw A, Butler R, Black F. The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained. In: 14th Annual British Thoracic Oncology Group Conference 2016. 2016, Dublin, Ireland: Elsevier.
• Roda D, Drew Y, Azaro A, Smith AD, Greystoke A, Sicart E, Escriba PV, Busquets X, Llado V, Tur V, Klumper E, Ahnert JR, Molife LR, Plummer R. A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM). In: 2015 American Society of Clinical Oncology Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
• Arkenau HT, Gazzah A, Plummer R, Blagden SP, Mak G, Soria JC, Greystoke A, Rizzuto I, Rogan D, Mazumdar J, Laubscher K, Auger KR, Swartz LS, Mattern ML, Nebot N, Singh RP, Fleming RA, Yan L. A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. In: American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. 2015, Chicago, Illinois, USA: American Society of Clinical Oncology.
• Greystoke A, Chaturvedi A. An Introduction to Stratified Medicine. Drug Discovery Today 2015, 20(12), 1409-1413.
• Greystoke A, Ayub M, Rothwell D, Morris D, Smith N, Carter L, Metcalf R, Blackhall F, Dive C, Brady G. Development of a Circulating miRNA Assay to Monitor Tumour Burden: from Mouse to Man. Cancer Research 2015. Submitted.
• Basu B, Dean E, Pugilisi M, Greystoke A, Ong M, Burke W, Harrington L, Green S, Olemann E, DeBono JS, Ranson M, Banerji U. First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clinical Cancer Research 2015, 21(15), 3412-3419.
• Iqbal MS, Paleri V, Brown J, Greystoke A, Dobrowsky W, Kelly C, Kovarik J. Spindle cell carcinoma of the head and neck region: Treatment and outcomes of 15 patients. ecancermedicalscience 2015, 9, 594.
• D'Arcangelo M, Margetts J, Greystoke A. The use of circulating biomarkers in early clinical trials in patients with cancer. Biomarkers in Medicine 2015, 9(10), 1011-1023.
• Hodgkinson CL, Morrow CJ, Li Y, Metcalf RL, Rothwell DG, Trapani F, Polanski R, Burt DJ, Simpson KL, Morris K, Pepper SD, Nonaka D, Greystoke A, Kelly P, Bola B, Krebs MG, Antonello J, Ayub M, Faulkner S, Priest L, Carter L, Tate C, Miller CJ, Blackhall F, Brady G, Dive C. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nature Medicine 2014, 20(8), 897-903.
• Molife LR, Dean E, BlancoCodesido M, Krebs MG, Brunetto A, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, deLasHeras B, Wood K, Ranson MR. A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research 2014, 20(24), 6284-6294.
• Bouranis L, Sperrin M, Greystoke A, Dive C, Renehan AG. 0 0 1 10 57 NICR, Newcastle University 1 1 66 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE The interaction between prognostic and pharmaco-dynamic biomarkers. British Journal of Cancer 2013, 109(7), 1782-5. In Preparation.
• Gibb A, Greystoke A, Ranson M, Linton K, Neeson S, Hampson G, Illidge T, Smith E, Dive C, Pettitt A, Lister A, Johnson P, Radford J. A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. British Journal of Cancer 2013, 109(10), 2560-2565.
• Greystoke A, Harris G, Jenkins M, Goonetilleke D, Moore D, Lancashire M, Ranson M, Hughes A, Clack G, Dive C. Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: A short communication. Journal of Pharmaceutical and Biomedical Analysis 2013, 84, 184-188.
• Moore DJ, Greystoke A, Butt F, Wurther J, Growcott J, Hughes A, Dive C. A Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis Patients. Clinical Drugs Investigation 2012, 32(3), 179-187.
• Dean E, Greystoke A, Ranson M, Dive C. Biomarkers of cell death applicable to early clinical trials. Experimental Cell Research 2012, 318(11), 1252-1259.
• Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, Priest LJ, Greystoke A, Zhou C, Morris K, Ward T, Blackhall FH, Dive C. Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. Journal of Clinical Oncology 2012, 30(5), 525-532.
• Greystoke A, Mullamitha SA. How Many Diseases Are Colorectal Cancer?. Gastroenterology Research and Practice 2012, 2012, 564741.
• Greystoke A, Ranson M. Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents. Annals of Oncology 2012, 23(8), 1934-1936.
• Greystoke A, Dean E, Saunders MP, Cummings J, Hughes A, Ranson M, Dive C, Renehan AG. Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer. British Journal of Cancer 2012, 107(9), 1518-1524.
• Greystoke A, OConnor JPB, Linton K, Taylor MB, Cummings J, Ward T, Hughes A, Maders F, Ranson M, Radford JA, Dive C. 0 0 1 15 88 NICR, Newcastle University 1 1 102 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer 2011, 104(4), 719-25. In Preparation.
• Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR. 0 0 1 20 118 NICR, Newcastle University 1 1 137 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. British Journal of Cancer 2011, 104(5), 750-5.
• Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ferraldeschi R, Hughes A, Clack G, Dive C, Blackhall FH. 0 0 1 22 130 NICR, Newcastle University 1 1 151 14.0 96 800x600 Normal 0 false false false EN-GB JA X-NONE Evaluation and prognostic significance of circulating tumour cells in patients with non small cell lung cancer (NSCLC). Journal of Clinical Oncology 2011, 29(12), 1556-63.
• Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C. Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Research and Treatment 2010, 120(2), 461-7.
• Greystoke A, Jodrell DI, Cheung M, Rivans I, Mackean MJ. How many cisplatin administration protocols does your department use?. European Journal of Cancer Care 2010, 19(1), 80-90.
• Brookes K, Cummings J, Backen A, Greystoke A, Ward T, Jayson GC, Dive C. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. British Journal of Cancer 2010, 102(10), 1524-32.
• Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. 175 2009, 2, 808-16.
• Board RE, Williams VS, Knight L, Shaw J, Greystoke A, Ranson M, Dive C, Blackhall FH, Hughes A. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Annals of New York Academy of Science 2008, 1137, 98.
• Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C. Optimisation of circulating biomarkers of cell death for routine clinical use. Annals of Oncology 2008, 19(5), 990-5. In Preparation.
• Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, DeBono JS, Steward W. A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of athree-weekly cycle in combination with carboplatin given on day 1 alone inpatients with advanced solid tumours. Annals of Oncology 2006, 17(8), 1313-9.
• Vidal L, Leslie M, Sludden J, Griffin MG, Plummer R, Judson I, Lee C, Greystoke A, Calvert AH, Boddy AV. A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98. In: 42nd Meeting of the American Society of Clinical Oncology Annual Meeting Proceedings. 2005, Orlando, Florida, USA: Journal of Clinical Oncology, American Society of Clinical Oncology.
• Wyatt N, Hogarth L, Turner D, Patterson M, Jamieson D, Black F, Hutton C, Mulvenna P, Simmons T, Bradshaw A, Kolenda C, Parker C, Martin-Ruiz C, Greystoke A. Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). In: IASLC 17th World Conference on Lung Cancer. 2016, Vienna, Austria: Elsevier.